Examples include EGFR and ALK inhibitors in non-small cell lung cancer, BRAF inhibitors in melanoma, HER2-targeting agents in breast cancer, and immune checkpoint inhibitors of CTLA4 or PDL1 in melanoma or non-small cell lung cancer 6-10. This evidence concerns the gene BRAF and non-small cell lung carcinoma.